Why is Novartis India falling/rising?

As of 19-Sep, Novartis India Ltd is currently priced at 905.70, reflecting an increase of 6.7 (0.75%). The stock has been gaining for the last two days, with a total return of 0.99% during this period, and it has outperformed its sector by 0.48%. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite a low debt-to-equity ratio and healthy long-term growth with a 61.43% annual increase in operating profit, the stock has underperformed significantly over the past year, generating a return of -14.56%. Additionally, while the company has shown positive results in the last three quarters, its expensive valuation, indicated by a Price to Book Value of 2.8, raises concerns among investors.
In the broader market context, Novartis India has underperformed the Sensex, which has gained 0.88% over the past week, while Novartis has declined by 1.35%. This trend continues over the longer term, with the stock down 4.78% over the past month compared to the Sensex's 1.20% increase. The low domestic mutual fund ownership, at only 0.01%, suggests a lack of confidence in the stock's current valuation, which may further contribute to its underperformance relative to the broader market. Overall, while there are some positive indicators for Novartis India, the combination of its recent price movements, valuation concerns, and broader market underperformance paints a complex picture for investors.